Skip to main content

TOP - March 2020, Vol 13, No 2

The March issue of The On­cology Pharmacist (TOP) features the latest medical news, expert perspectives, clinical trial results, and drug updates, as well as important highlights from national and international meetings, including the 2019 ASH annual meeting, the 2019 Supportive Care in Oncology Symposium, the NCCN 2019 Hematologic Malignancies meeting, the ACCC 2019 National Oncology Conference, and the 2019 AVBCC Summit. Read More ›

Orlando, FL—Chimeric antigen receptor (CAR) T-cell therapy is now approved as third-line treatment for patients with B-cell lymphomas and leukemias. For some patients, CAR T-cell therapy is a miracle therapy, extending survival and, in some cases, as a bridge to a potentially curative transplant. Read More ›

Orlando, FL—Nivolumab monotherapy can be used as an effective bridge therapy to autologous hematopoietic cell transplantation (AHCT) in many patients with relapsed or refractory Hodgkin lymphoma (HL), researchers reported at the 2019 American Society of Hematology (ASH) annual meeting. Read More ›

New York City, NY—By its very nature, oncology is rife with change, with new research resulting in treatment advances at a rapid pace. Pending federal legislation aimed at reining in prescription drug prices and an upcoming presidential election may introduce yet further changes in oncology. Read More ›

San Francisco, CA—According to results from a retrospective analysis of nearly 12,000 patients with cancer, increased social support may function as an analgesic and help to mitigate pain. Read More ›

Orlando, FL—The impact of poverty and low socioeconomic status on health and survival among children may be even more debilitating than suspected, according to new data presented at ASH 2019. Read More ›

New York City, NY—With cancer drugs representing some of the most expensive pharmaceuticals on the market, conversations abound around value in oncology and proposed solutions for achieving it. Read More ›

Orlando, FL—A new CD45-targeting antibody radiation-conjugate, iodine-­131 (I-131) apamistamab, may be a less toxic alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens before initiation of adoptive cell therapy, according to results presented at ASH 2019. Read More ›

Orlando, FL—Mosunetuzumab is an investigational bispecific T-cell engager (BiTE) agent dually targeting 2 proteins on the surface of lymphoma cells—CD3 (on the surface of T-cells) and CD20 (on the surface of B-cells). Read More ›

Orlando, FL—Tazemetostat, a first-in-class EZH2 inhibitor, has demonstrated single-agent antitumor activity in patients with relapsed or refractory follicular lymphoma, according to data presented at ASH 2019. Read More ›

Page 1 of 2